Danica Pension Livsforsikringsaktieselskab Acquires New Stake in Stryker Corporation $SYK

Posted by Stanley Muller on Aug 19th, 2026

Danica Pension Livsforsikringsaktieselskab bought a new position in Stryker Corporation (NYSE:SYK – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,607 shares of the medical technology company’s stock, valued at approximately $3,654,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares in the last quarter. KCM Investment Advisors LLC boosted its stake in Stryker by 1.5% during the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after buying an additional 28 shares in the last quarter. Rossby Financial LCC grew its holdings in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the period. Tcfg Wealth Management LLC raised its position in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares in the last quarter. Finally, West Michigan Advisors LLC lifted its holdings in Stryker by 0.4% in the 4th quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company’s stock valued at $2,631,000 after acquiring an additional 30 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SYK. JPMorgan Chase & Co. lowered their price objective on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Raymond James Financial set a $370.00 target price on shares of Stryker in a report on Friday, July 31st. Truist Financial upped their price target on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a report on Friday, July 31st. Leerink Partners cut their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Get Our Latest Stock Report on SYK

Stryker Stock Performance

Stryker stock opened at $331.96 on Wednesday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The firm’s 50 day simple moving average is $325.56 and its 200-day simple moving average is $333.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $127.33 billion, a P/E ratio of 34.40, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the firm earned $3.13 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Activity

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 315,370 shares of company stock worth $98,463,501. 4.60% of the stock is owned by corporate insiders.

About Stryker

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.